Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the
treatment and secondary prevention of venous thromboembolism (VTE). Like other direct …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Eliquis™(apixaban) is the culmination of an intense medicinal chemistry effort to identify a
highly optimized inhibitor of coagulation factor Xa (FXa). We sought to identify a safe and …

The direct factor Xa inhibitor apixaban (Eliquis®) has predictable pharmacodynamics and
pharmacokinetics and does not require routine anticoagulation monitoring. This article …

Apixaban, a direct orally active anticoagulant (selective, direct factor Xa inhibitor) is
approved for (primary) prevention of venous thromboembolism (VTE) in patients undergoing …

Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …